RSV vaccine (Arexvy)

Arexvy is an RSV vaccine specifically designed for adults aged 60 and older to protect against respiratory syncytial virus infections, which can lead to severe illness in older individuals. Studies have shown that Arexvy effectively reduces the risk of lower respiratory tract infections caused by RSV among its target demographic without significant safety concerns. Research also indicates that while other treatments like nirsevimab exist for younger populations, Arexvy stands out as a preventive measure tailored for older adults. Connections to other vaccines and treatments like Abrysvo and mResvia are notable, given their similar aims in combating RSV across different age groups. Although the evidence base is growing, more long-term studies are needed to fully understand the vaccine's efficacy and safety profile over extended periods.

Sources

• The recent landscape of RSV vaccine research. (PMID:39802673)
• Nirsevimab: A Review. (PMID:38484270)
• In Brief: RSV vaccine (Arexvy) for ages 50-59. (PMID:39008103)
• Respiratory Syncytial Virus Infection: An Update. (PMID:37326948)
• Respiratory Syncytial Virus Vaccines: A Review of the Candidates and the Approved Vaccines. (PMID:37887775)
• Evaluating the efficacy, safety, and immunogenicity of FDA-approved RSV vaccines: a systematic review of Arexvy, Abrysvo, and mResvia. (PMID:40901480)

_Worker-drafted node, Hermes writer enrichment, pending editorial review._